Skip to main content

Hemophilia Market: Growth, Share, Demand and Analysis of Key Players to 2027

Page 1

Hemophilia Market Analysis, Size, Growth, Share, Outlook & Forecast to 2027

The global hemophilia market size is expected to reach USD 18.1 billion by 2027, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.5% over the forecast period. Increasing awareness of early diagnosis and treatment coupled with supportive government policies is anticipated to boost market share over the forecast period. For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention. In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders. The key market companies are projected to adopt strategic initiatives including geographic expansion and R&D especially in developing and underdeveloped regions, such as Middle Eastern and West African countries.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/hemophiliatreatment-industry


For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials. Furthermore, in June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi’s BIVV001 based on its preclinical study results. Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally. Further key findings from the report suggest: 

Hemophilia A held the largest market share in 2019 due to its increasing prevalence worldwide

Type B is expected to be the fastest growing type over the forecast period, at a CAGR of 6.8%

On-demand dominated the treatment segment over the forecast period and is expected to contribute majority of the share in 2019

Prophylaxis is estimated to be the fastest growing segment over the forecast period

Replacement therapy was expected to be the largest segment in 2019

Gene therapy dominated the therapy segment over the forecast period owing to increasing involvement of companies to develop more gene therapy for its treatment

Increasing research and development and strategic collaborations are key strategies undertaken by major players in the market space.

Grand View Research has segmented the global hemophilia market based on type, treatment, therapy, and region: Hemophilia Type Outlook (Revenue, USD Million, 2016 - 2027)  Hemophilia A 

Hemophilia B

Hemophilia C

Others

Hemophilia Treatment Outlook (Revenue, USD Million, 2016 - 2027)  On-demand 

Prophylaxis

Get Sample Copy of Report @ https://www.grandviewresearch.com/industryanalysis/hemophilia-treatment-industry/request/rs1 Hemophilia Therapy Outlook (Revenue, USD Million, 2016 - 2027)  Replacement therapy 

ITI therapy

Gene therapy


Hemophilia Regional Outlook (Revenue, USD Million, 2016 - 2027)  North America

o

U.S.

o

Canada

Europe o

U.K.

o

Germany

o

France

o

Italy

o

Spain

Asia Pacific o

Japan

o

China

o

India

o

South Korea

o

Australia

Latin America o

Brazil

o

Mexico

o

Argentina

o

Colombia

Middle East & Africa o

South Africa

o

UAE

o

Saudi Arabia

Table of Content Chapter 1. Methodology and Scope 1.1. Market segmentation & scope 1.2. Information procurement 1.2.1. Purchased database 1.2.2. GVR’s internal database


1.2.3. Secondary sources & third party perspectives 1.2.4. Primary research 1.3. Information analysis 1.3.1. Data analysis models 1.4. Market formulation & data visualization 1.5. Data validation & publishing Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Insights Chapter 3. Hemophilia Market Variables, Trends & Scope 3.1. Market Lineage outlook 3.1.1. Parent/ Ancillary market outlook 3.2. Penetration & Growth Prospect Mapping 3.3. Product Pipeline Analysis 3.4. Regulation Framework Continue…………. About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com


Turn static files into dynamic content formats.

Create a flipbook
Hemophilia Market: Growth, Share, Demand and Analysis of Key Players to 2027 by Grand View Research Research - Issuu